Literature DB >> 16022924

HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients.

Ozden Altundag, Kadri Altundag, Bulent Ozcakar, Yavuz S Silay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16022924     DOI： 10.1016/j.lungcan.2005.02.013

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  2 in total

Review 1.  The HER family and cancer: emerging molecular mechanisms and therapeutic targets.

Authors:  Natalia V Sergina; Mark M Moasser
Journal:  Trends Mol Med       Date:  2007-11-05       Impact factor: 11.951

2.  Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab.

Authors:  Alejandro Vazquez-Martin; Cristina Oliveras-Ferraros; Javier A Menendez
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.